Sylvia C Kurz
Overview
Explore the profile of Sylvia C Kurz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
382
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kotecha R, Akdemir E, Kutuk T, Ilgin C, Ahluwalia M, Bi W, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39807850
Background: Despite advances in our understanding of the molecular underpinnings of meningioma progression and innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge. The objective of...
2.
Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, et al.
J Clin Oncol
. 2024 Feb;
42(13):1542-1552.
PMID: 38335473
Purpose: Histone 3 (H3) K27M-mutant diffuse midline glioma (DMG) has a dismal prognosis with no established effective therapy beyond radiation. This integrated analysis evaluated single-agent ONC201 (dordaviprone), a first-in-class imipridone,...
3.
Ranjan S, Leung D, Ghiaseddin A, Taylor J, Lobbous M, Dhawan A, et al.
Cancer
. 2024 Jan;
130(9):1577-1589.
PMID: 38288941
Management of venous thromboembolism (VTE) in patients with primary and metastatic brain tumors (BT) is challenging because of the risk of intracranial hemorrhage (ICH). There are no prospective clinical trials...
4.
Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, et al.
Clin Cancer Res
. 2023 Dec;
30(4):680-686.
PMID: 38048045
Purpose: There are no effective medical therapies for patients with meningioma who progress beyond surgical and radiotherapeutic interventions. Somatostatin receptor type 2 (SSTR2) represents a promising treatment target in meningiomas....
5.
Kurz S, Stammberger A, Rosahl S, Abrey L, Albert N, von Baumgarten L, et al.
Neuro Oncol
. 2023 Sep;
25(12):2302-2304.
PMID: 37738478
No abstract available.
6.
Karschnia P, Kurz S, Brastianos P, Winter S, Gordon A, Jones S, et al.
Neurology
. 2023 Aug;
101(17):e1741-e1746.
PMID: 37527941
Objectives: The folate antagonist high-dose methotrexate (HD-MTX) is integral to induction chemotherapy for primary CNS lymphoma (PCNSL); however, it can be associated with leukoencephalopathy. Methylenetetrahydrofolate reductase (MTHFR) is involved in...
7.
Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, et al.
Neurooncol Adv
. 2023 Jul;
5(1):vdad076.
PMID: 37476329
Background: Central nervous system (CNS) cancer is the 10th leading cause of cancer-associated deaths for adults, but the leading cause in pediatric patients and young adults. The variety and complexity...
8.
Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, et al.
Neurooncol Adv
. 2023 Mar;
5(1):vdad012.
PMID: 36915613
Background: The clinical utility of molecular profiling and targeted therapies for neuro-oncology patients outside of clinical trials is not established. We aimed at investigating feasibility and clinical utility of molecular...
9.
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, et al.
Neurooncol Adv
. 2022 Nov;
4(1):vdac163.
PMID: 36382106
Background: Hyperglycemia has been associated with worse survival in glioblastoma. Attempts to lower glucose yielded mixed responses which could be due to molecularly distinct GBM subclasses. Methods: Clinical, laboratory, and...
10.
de Groot J, Kim A, Prabhu S, Rao G, Laxton A, Fecci P, et al.
Neurooncol Adv
. 2022 May;
4(1):vdac040.
PMID: 35611270
Background: Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry...